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Background: Venous thromboembolism is common in patients with cancer and requires anticoagulation with low
molecular weight heparin. Current data informs anticoagulation as far as six months, yet guidelines recommend
anticoagulation beyond six months in patients who have locally advanced or metastatic cancer. This
recommendation, based on expert consensus, has not been evaluated in a clinical study. ALICAT (Anticoagulation
Length in Cancer Associated Thrombosis) is a feasibility study to identify the most clinically and cost effective
length of anticoagulation with low molecular weight heparin in the treatment of cancer associated thrombosis.
Methods/Design: ALICAT is a randomized multi-centre phase two mixed-methods study with three components: a
randomized controlled trial, embedded qualitative study and a survey investigating pathways of care. The randomized
controlled trial will compare ongoing low molecular weight heparin treatment for cancer-associated thrombosis versus
cessation of low molecular weight heparin at six months treatment (current licensed practice) in patients with locally
advanced or metastatic cancer. The embedded qualitative study will include focus groups with clinicians to investigate
attitudes to recruiting to the study, identify the challenges of progressing to a full randomized controlled trial, and also
semi-structured interviews with patients and relatives/carers to explore their attitudes towards participating in the study
and potential barriers and concerns to participation. Finally, a UK wide survey exercise will be undertaken to develop a
classification and enumeration system for the cancer associated thrombosis models and pathways of care.
Discussion: There is a lack of evidence determining the length of anticoagulation for patients with cancer associated
thrombosis and subsequently treatment length varies. The ALICAT study will consider the feasibility of recruiting
patients to a phase three trial.
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Venous thromboembolism (VTE), comprising of deep
vein thrombosis (DVT) and pulmonary embolus (PE), is a
common phenomenon which occurs in 1 in 1,000 patients
and annually affects 6.5 million people worldwide [1,2].
Within the UK, the cost of managing VTE has been esti-
mated at £640 million per year, and the prevention of
VTE has become a health service priority [3]. Individuals
with cancer are at particular risk of VTE due to the local
release of procoagulants, such as tissue factor, and the
prothrombotic nature of oncological treatments including
surgery, chemotherapy and radiotherapy [4]. Up to 18% of
patients with cancer will develop VTE, requiring anticoa-
gulation [4]. The standard treatment of VTE is well estab-
lished, consisting of five days anticoagulation with low
molecular weight heparin (LMWH), followed by three to
six months warfarin [4,5]. However, the management of
cancer associated thrombosis (CAT) presents several chal-
lenges due to a higher rate of both re-thrombosis and
bleeding amongst patients with cancer when compared to
those with a non-malignant disease [6].
The impact of VTE on patients with cancer is substan-
tial; conferring a worse prognosis when compared with
similar stage cancer patients without VTE [7,8]. Further-
more, anticoagulation with warfarin is complicated by
drug-drug interactions, variable drug absorption, and chan-
ging nutritional status [9]. This inevitably has a practical
impact on the delivery of anti-cancer therapies. Maintain-
ing stable coagulation with warfarin is difficult and requires
more frequent monitoring with blood tests, which ad-
versely affects patients’ quality of life [10]. Three random-
ized controlled trials (RCTs) have compared LMWH with
warfarin in the treatment of CAT, demonstrating superior
efficacy with LMWH without statistical difference in
bleeding complications [11-13]. Consequently, national
and international clinical guidelines recommend the
gold standard treatment of CAT to be six months
treatment with weight adjusted LMWH [6,14-16].
The management of CAT beyond six months is less
clear; in patients with locally advanced or metastatic
cancer there is an ongoing prothrombotic state which
may warrant anticoagulation beyond the recommended
period. In support of indefinite anticoagulation are data
suggesting the prothrombotic risk increases with disease
progression, due to a greater tumor burden, reduced per-
formance status and increased use of palliative chemotherapy[17-19]. However, with cancer progression also comes an
increased bleeding risk during anticoagulation, and the de-
cision to anticoagulate indefinitely will need to balance
the benefits of preventing recurrent VTE against the risks
of major bleeding [20,21]. Furthermore, it is important to
consider the impact of long term LMWH use on patients’
quality of life.
Currently, clinical guidelines recommend clinicians con-
sider continuing anticoagulation indefinitely in patients
with locally advanced or metastatic cancer [15,16,22]. Such
recommendations are based largely on consensus opinion
and, to date, have been supported by limited clinical evi-
dence beyond case series and observational studies [23,24].
In the recently reported DALTECAN (Dalteparin sodium
for the long-term management of venous thromboembol-
ism in cancer patients) study, 334 patients with VTE and
locally advanced or metastatic cancer were treated with dal-
teparin, of whom 185 (55.4%) completed six months of
therapy and 109 (33%) completed twelve months [24]. The
authors reported a 10.2% overall frequency of major bleed-
ing and an overall incidence of new or recurrent VTE of
11.1%. In patients treated during the extended anticoagula-
tion period, new or recurrent VTE was reported in 4.1% of
patients and major bleeding at a rate of 4.2%. It is notable
that both bleeding and recurrent thrombosis rates were
higher in the first six months of anticoagulation (1.3% and
1.4% per patient-month respectively) compared with months
seven to twelve (0.7% and 0.7% per patient-month respect-
ively) [24]. In the absence of a control arm in which patients
received placebo/ceased anticoagulation at six months,
the study offers no further guidance as to whether antic-
oagulation beyond six months provides any net benefit.
However, it offers valuable data, which can be used to in-
form future clinical studies. Firstly, with 96% trial adher-
ence, it suggests that the use of LMWH beyond six
months is feasible within the trial setting. Secondly, it sug-
gests that safety concerns regarding bleeding in this patient
group may be less of an issue than previously believed. Fur-
thermore, with the rate of VTE recurrence being lower dur-
ing the extended anticoagulation period than the initial six
months, it would seem reasonable to question what degree
of added clinical benefit is gained through extended treat-
ment, rather than ceasing anticoagulation at six months
[24]. Finally, the trial did not formally evaluate quality
of life aspects of LMWH administration over an extended
time period.
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CAT management beyond six months anticoagulation. In
the LONGHEVA (Long-term Treatment for Cancer Pa-
tients With Deep Venous Thrombosis or Pulmonary Em-
bolism) [25] study patients who have completed six to
twelve months of treatment for VTE and still have an indi-
cation for further anticoagulation (metastatic cancer and/or
ongoing cancer treatment) will be randomized to receive a
further six months of vitamin K antagonist (VKA) or
LMWH. The primary efficacy outcome is recurrence of
confirmed symptomatic DVT with secondary outcomes in-
cluding safety. Driven by the belief that patients with meta-
static cancer or receiving cancer treatment require
extended anticoagulation, the investigators seek to establish
the most efficacious anticoagulant between VKAs and
LMWHs [25]. Whilst the driving hypothesis feels intuitively
sensible, this belief is yet to be quantified within the trial
setting. Without robust data identifying the VTE risk of not
continuing anticoagulation it becomes conceptually chal-
lenging to justify a therapeutic intervention that is yet to be
proven beneficial.
SELECT-D (Anticoagulation therapy in SELECTeD
cancer patients at risk of recurrence of venous thrombo-
embolism.) is a pilot study comparing dalteparin versus
rivoraxaban in the treatment of CAT with a second
placebo-controlled randomization comparing the dur-
ation of anticoagulation therapy (six months versus
twelve months treatment) in residual vein thrombosis
[RVT] positive patients [26]. It is wholly appropriate that
this study is piloted before proceeding to a full RCT
since several key factors within the study design will
need clarification in advance. Firstly, the investigators
have chosen to compare dalteparin with rivaroxaban, a
drug that is yet to demonstrate non-inferiority in the
CAT setting. Secondly, the utility of RVT as a predictor
of VTE recurrence specifically in the cancer-associated
thrombosis setting is yet to be established [27,28].
It is arguable that when considering anticoagulation be-
yond six months, one should quantify the clinical need for
prolonged anticoagulation before evaluating the most
appropriate drug. Scientifically, such an approach has merit
since it informs future studies from a basis of fact and not
supposition. However, clinical practice has developed
in such a way that many clinicians will continue anticoagu-
lation regardless of the evidence deficit. For this reason, a
study to identify whether patients with CAT and ongoing
cancer should cease or continue anticoagulation at six
months may be difficult to recruit to, since such practice
feels counter intuitive to clinicians. Whether such a study
would be feasible regardless of scientific merit is unclear.
The authors therefore propose such a study to identify the
feasibility of conducting a RCT comparing six months
LMWH with indefinite anticoagulation in CAT patients
with ongoing malignancy.Research aim and objectives
The ALICAT (Anticoagulation Length in Cancer Associ-
ated Thrombosis) study was developed in response to a
National Institute for Health Research (NIHR) Health
Technology Assessment (HTA) commissioned call con-
sidering duration of treatment of venous thromboembol-
ism in malignant disease (reference: 10/145), to address
a specific gap in the evidence base for the management
of CAT in patients with ongoing malignant disease.
The aim of this study is to examine the feasibility of
conducting a phase three randomized controlled trial de-
termining the length of anticoagulation for patients with
cancer associated thrombosis.
The objectives are to: (1) Identify the practicalities of
conducting a full RCT with regard to recruitment, reten-
tion and outcome measurement, specifically: the number
of eligible patients that can be recruited within a one
year timeframe, the dropout rate, the practical utility of
measuring primary outcome measures, reporting pro-
cesses, and assessment tools within the context of a full
RCT. (2) Explore the logistical and attitudinal barriers to
progressing to a full RCT, in particular: how and where
to identify patients for recruitment, the attitudes of clini-
cians towards entering patients on to the ALICAT trial
and prescribing anticoagulation for patients with CAT,
patients’ attitudes to taking part in the trial, including in-
dividuals who consented, those who refused to partici-
pate and people who withdrew post-randomization.
Methods/Design
Study design
The ALICAT trial schema is summarized in Figure 1.
ALICAT is a mixed-methods study involving three com-
ponents: a RCT, an embedded qualitative study that will
include focus groups with clinicians and interviews with
patients and their relatives, and a UK wide survey exer-
cise to map patient pathways. Each component of the
study is explained below.
Randomized controlled trial
This component of the study comprises an open-label
two arm RCT comparing ongoing LMWH treatment
for CAT versus cessation of LMWH at six months treat-
ment (current licensed practice) in patients with locally
advanced or metastatic cancer.
Participant recruitment
In order to assess the feasibility of recruiting sufficient
numbers of patients to inform a full phase three RCT,
the ALICAT study will evaluate recruitment of patients
from three different care settings within the UK: oncol-
ogy outpatients, hematology outpatients, and primary
care. Index VTE events shall be identified through pri-
mary and secondary care clinical databases and clinical
secondary care clinical databases and clinical records 
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Figure 1 Trial schema.
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tings, potential participants will already be attending out-
patient clinics for management of their cancer or CAT,
and potential participants will be screened by a re-
searcher and notified to the site principal investigator.
Within the primary care setting, electronic patient re-
cords will be used to identify patients receiving treatment
doses of LMWH. These records will be screened for pa-
tient eligibility of registration, by a researcher based in a
primary care research institution. Patients who meet the
eligibility criteria will be invited to the participating prac-
tice in order to consider participating in the study. The
search will be repeated monthly in order to identify inci-
dent cases.Potential patients will be identified when they are ap-
proaching completion of their first five months treatment
with LMWH for CAT. Suitable patients will be anonym-
ously registered. After written informed consent has been
obtained, a screening baseline assessment will be conducted
to ensure all the inclusion and exclusion criteria are met
(see Table 1). Patients who meet the eligibility criteria will
be randomized by the coordinating trials unit to either the
treatment arm (continue LMWH treatment for a further
six months) or the control arm (discontinue LMWH),
using block randomization with varying block sizes and a
1:1 allocation ratio. Randomized patients will be asked to
complete three baseline quality of life questionnaires
(EORTC QLQ-C30, E5D-5 L and ESAS-r), and to keep a
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ive of the trial arm assigned.
Information on all potentially eligible patients will be re-
corded, including whether or not patients were actually eli-
gible for the trial, if they were approached about the trial, if
they agreed to randomization, or were approached about
taking part in a qualitative interview. Where possible, infor-
mation on why the patient was not approached, random-
ized or approached for the qualitative interview will also be
recorded.Trial treatment arm
Participants randomized to the treatment arm will have
already received LMWH (dalteparin (Fragmin®), enoxaparin
(Clexane®), or tinzaparin (Innohep®)) at the treatment dose
for six months. As this is a pragmatic feasibility study, par-
ticipating clinicians’ treatment practices will not be altered
and participants will continue with the same LMWH.Table 1 Inclusion/exclusion criteria and initial assessment
for the ALICAT trial
Inclusion criteria 1. Receiving LMWH for treatment of CAT for
approximately five months
2. Locally advanced or metastatic cancer
3. Able to self-administer LMWH, or have LMWH
administered by a carer (routine administration
by a district nurse is not permissible)
4. Able to give informed consent
5. Age ≥16 years.
Exclusion criteria 1. Receiving drug other than LMWH for CAT
2. Contraindication to continuing anticoagulation:
a. Known allergies to LMWHs, heparin, sulfites
or benzyl alcohol,
b. Active major bleeding,
c. History of heparin-induced thrombocytopenia,
d. Known poor compliance with LMWH,
3. Confirmed recurrent VTE whilst receiving
anticoagulation
4. Fitted with a prosthetic heart valve.
Initial assessment 1. Full blood count, urea, electrolytes, liver
function, bone profile
2. Physical examination
3. Primary tumor and tumor treatment history
4. Details of LMWH treatment off-trial
5. Baseline concomitant medications
6. Baseline comorbidities (including index VTE
and bleeding event history)
7. Use of NHS resources three months prior to
commencing trial treatment.
CAT, Cancer associated thrombosis; LMWH, Low molecular weight heparin;
NHS, National Health Service; VTE, Venous thromboembolism.LMWH will be given as a daily subcutaneous dose at the
same dose and time as previously administered over the
previous six months. Dosing levels will be guided by the
Summary of Product Characteristics (SPC) as described in
Table 2.
Switching from one ALICAT Investigational Medicinal
Product (IMP) to another during the trial treatment
period is allowed if deemed necessary by the treating
clinician. Within current practice, the dose of LMWH
may be altered at the discretion of the supervising clin-
ician as described in Table 3. Any alteration of LMWH
administration or dose and any episodes of bleeding or
recurrent VTE will be documented.
LMWH supply
As ALICAT is a pragmatic trial, it is not the intention to
change the way the LMWH is normally prescribed. A clin-
ical trial labelling exemption has been obtained from the
Medicines and Healthcare products Regulatory Authority
(MHRA) and the trial will be fully exempt from the UK
statutory instrument The Medicines for Human Use (Clin-
ical Trials) Regulations 2004 No. 1031 Part 7 Regulation 46
with respect to IMP labelling and dispensing. The LMWH
will be prescribed by the participant’s general practitioner
(GP), oncologist or hematologist according to pre-existing
local arrangements. The drug will be dispensed from com-
mercial stock through local hospital pharmacies and com-
munity pharmacies. It is anticipated that excess treatment
costs will only be incurred for participants allocated to the
treatment arm at participating sites where currently it is
not common practice to extend LMWH treatment for
CAT beyond six months. Excess treatment costs will not be
incurred for participants allocated to the control arm of the
trial, irrespective of the local policy for extended LMWH
treatment.
RCT sample size calculation
We anticipate there being at least 200 eligible patients per
year in total from all three recruitment settings. We assume
that not all patients who have been injecting LMWH for
five months will agree to continue for a further six months.
We are not sure what proportion of patients will be willing
to be randomized, but we consider that at least 30% will
need to agree in order to make a phase three RCT worth-
while. Therefore, the ALICAT study will aim to assess the
feasibility of randomization by determining if at least 30%
of potential patients will agree to randomization. We will
then calculate the precision of this proportion with a 95%
confidence interval. We will also estimate the proportion of
patients who experience recurrent VTEs during follow up,
which will inform the design of the phase three RCT.
If less than 15% of eligible patients agree to take part in
the trial, a phase two RCT may not be suitable as we may
not be able to recruit suitable numbers, given that a larger
Table 2 Recommended LMWH dose levels
LMWH Month one Month two to six Entry to ALICAT
Dalteparin (Fragmin®) 200 International Units/kg total body weight,
once daily
150 International Units/kg total body weight,
once daily
Dose as detailed at
month six
Tinzaparin (Innohep®) 175 International Units/kg total body weight,
once daily
175 International Units/kg total body weight,
once daily
Dose as detailed at
month six
Enoxaparin (Clexane®) 150 International Units/kg total body weight,
once daily
150 International Units/kg total body weight,
once daily
Dose as detailed at
month six
ALICAT, Anticoagulation Length with low molecular weight heparin In the treatment of Cancer Associated Thrombosis; LMWH, Low molecular weight heparin;
kg, kilogram.
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teria as a result of this feasibility study. If at least 30% agree
to take part, then we would consider that randomizing pa-
tients to a larger phase three trial would be feasible. Using a
Fleming’s single stage design, setting p1 to 0.15 and p2 to
0.3, and with 5% significance and 90% power, then we will
need to approach 62 eligible participants with details of the
trial. This design requires that at least 15 out of 62 partici-
pants consent to the trial. We therefore propose a two-
stage sample size. If at least 15 out of the first 62 partici-
pants recruited to the trial accept randomization, then we
will continue recruitment into stage two. If fewer than 15
patients agree, we will determine at this stage that
randomization within this population is not feasible.
If we expect that 200 will be the maximum potential
number of eligible patients, then we can expect to be
able to produce a 95% confidence interval for the per-
centage willing to be randomized of width 13.7% or less.
For example, if the percentage is 50%, then we could ex-
pect the 95% confidence interval to be 43.15 to 56.85%.
If the percentage is 30% we can expect a slightly smaller
confidence interval of 23.7 to 36.3%. If only 150 patients
are deemed eligible, then we can expect to calculate a 95%
confidence interval for 50% randomized of 42.1 to 57.9%.
Our target registration number for this feasibility trial is
therefore 200 patients, of which we hope that at least 60 pa-
tients will be randomized into the two groups. Thirty pa-
tients per arm will provide enough power to create a 95%
confidence interval around the risk of VTE recurrence,
which would have a width of 34% or less. As an example, ifTable 3 Permissible LMWH dose alterations
Reason for increasing dose
of LMWH:
Recurrence of symptomatic VTE despite adm
measurements of anti-Xa levels to guide LM
Reason for decreasing dose: Sometimes patients may experience minor
clinical decision of the supervising clinician
VTE should LMWH be stopped or major ble
Dose for obese patients: Follow the SPC or local clinical practice.
Dose for renal impairment: Follow the SPC. Patients with renal impairm
anti factor Xa levels according to local polic
LMWH, Low molecular weight heparin; SPC, summary of product characteristics; VTwe found that the risk of VTE occurrence was 50% in the
arm that stopped, we would be able to estimate a confidence
interval of approximately 33% to 67% or smaller. If the risk
of VTE were 8%, the confidence interval would be 0 to 19%.RCT data collection
Participants randomized to the RCT will be seen at the
recruiting hospital clinical or GP practice (as appropri-
ate) approximately 12 and 26 weeks after starting a fur-
ther six months treatment with LMWH (treatment arm)
or after stopping treatment with LMWH after six
months treatment off-trial (control arm). Assessments
will include VTE treatment and compliance, physical
assessment, full blood count, urea, electrolytes, liver
function test, bone profile, toxicities, concomitant medi-
cations, use of NHS resources (hospital admissions, GP
visits, nurse visits: details to be taken from patient diary
booklet and patient notes), and quality of life question-
naires (EORTC QLQ-C30, E5D-5 L and ESAS-r). VTE,
bleeding events, and serious adverse events will be col-
lected in real time. Adverse events, in particular the sec-
ondary outcomes of recurrent VTE or hemorrhagic
events, will be monitored by the Independent Data
Monitoring Committee. In the event of excessive bleed-
ing or thrombotic events, this committee will advise on
early closure of the trial if necessary. Research staff at
recruiting sites will be expected to complete trial case
report forms (CRFs) that record evidence of primary and
secondary outcome measures. Patients will also be askedinistration of weight adjusted dose as per SPC. Some clinicians may use
WH dosing in this situation.
bleeding which will resolve on decreasing the dose of LMWH. This is a
that will be made based on balancing the perceived risks of recurrent
eding should LMWH be continued.
ent should have dose adjustment depending on creatinine clearance/
y.
E, venous thromboembolism.
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lected and to be registered with NHS Information
Centre Flagging so that the date and cause of death can
be collected without longer term follow up.
Statistical analysis
All analyses will be performed on a full intention-to-
treat basis, (all patients randomized will be included)
and all patients will be analyzed according to their allo-
cated group, whichever treatment they received. We will
calculate the percentage of registered patients who were
randomized, with 95% confidence interval. We will also
calculate the percentage of patients experiencing recur-
rent VTE recurrence and bleeding events in both groups
with 95% confidence intervals. The percentage of pa-
tients who died within six months of randomization will
be calculated in both arms, along with the percentage of
patients who successfully completed six months of trial
treatment in the LMWH group. The median QLQ-C30
raw and linear transformed functional scales will be cal-
culated and presented for both arms of the study. No
formal subgroup analyses are planned. However, if any
treatment effect is found we will investigate whether it is
consistent across participant subgroups (defined by all
pre-treatment factors collected) although this analysis
will be exploratory in nature. Exploratory analyses may
be conducted to aid hypothesis generation if a phase
three RCT is subsequently developed.
Embedded qualitative study
To explore clinicians’ attitudes towards the trial and
patients’ and their relatives’ experiences of participat-
ing in the trial, an embedded qualitative study will be
undertaken as part of the larger study. The embedded
qualitative study will include focus groups with clinicians
and semi-structured interviews with patients and their
relatives.
Clinician focus groups
Focus groups will be conducted with clinicians from
oncology, hematology and primary care settings. Six
to ten clinicians will be recruited per group, to enable
a variety of perspectives while also ensuring that
participants have the opportunity to take part in a dy-
namic discussion [29]. Two focus groups per clinical
setting will be undertaken in order to promote trust-
worthiness of the findings [29]. Where feasible, for
the ease of participants and to not limit the sample
to clinicians working in one geographical area [30],
focus groups will be held at national meetings and
educational events. This has previously been under-
taken successfully with clinicians who would other-
wise be challenging to recruit to individual interviews
of focus groups in other settings [31]. A volunteersample of clinicians from each clinical setting will be
recruited to the focus groups, through advertising the
group in the conference literature and via social network-
ing, with clinicians encouraged to contact the researchers
or attend on the day.
The focus group will be facilitated by two experi-
enced researchers, with one researcher taking the lead
and the other documenting non-verbal communica-
tion and ensuring that all participants have the
opportunity to participate. It can be challenging to
encourage participants to discuss issues relevant to
them while ensuring that the research objectives are
addressed [29] and therefore a topic guide will be
developed that addresses: participants’ attitudes to
recruiting to the study in terms of recruitment,
equipoise, acceptability of intervention and outcome
measures; and participants’ experiences of and atti-
tudes to prescribing LMWH, including whether they
would extend treatment past six months. However,
the researchers will also encourage participants to
explore issues pertinent to them.
Semi-structured interviews
This component of the study will explore patients’
and their relatives’ attitudes towards participating in
the RCT, potential barriers to and concerns about
participation, and factors influencing adherence with
self-injection (where appropriate). The most appropriate
method for exploring these issues is semi-structured in-
terviews [32], which will be undertaken with: patients
who decline randomization, trial participants in the
intervention arm, trial participants in the control arm,
relatives/carers or trial participants (such as a partner,
relative or friend), and participants who withdraw from
the intervention or control arm.
In total, 50 to 75 participants will be recruited,
including 10 to 15 per group. While this is arguably
a large sample size for a qualitative study, it is im-
portant to ensure that sufficient numbers of patients
are included from each group to promote a variety
of perspectives and experiences within the sample.
A convenience sample of participants will be re-
cruited from the RCT, a common sampling strategy
for embedded qualitative studies within trials [33].
All eligible patients taking part in the RCT will
be approached until sufficient numbers have been
recruited to represent all groups. Initially, partici-
pants will be approached by research practitioners at
the recruiting site. When signing the consent form
for the RCT component of the study, patients will be
able to indicate if they consent to being contacted by
the qualitative researcher to discuss being inter-
viewed. The research practitioner will then provide
the qualitative researcher with the contact details of
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contact participants to discuss the interview study,
and if the patient agrees, arrange a convenient time
and location for interview. LMWH is a home-based
treatment and a proportion of relatives assume a car-
ing role in administering the medication. Relatives
and/or carers will therefore be recruited by patients
taking part in the RCT, enabling patients to have
control about who they include [34].
It is anticipated that the interview will take place
in the person’s home, for their convenience and for
the researcher to be able to speak to the person in
their natural environment [35], but can be under-
taken in a quiet clinic location if preferred by the
participant. The qualitative researcher will take writ-
ten informed consent immediately prior to the inter-
view where appropriate. Interviews will usually be
between 30 and 60 minutes in length, but will be
terminated earlier if the participant becomes unwell.
Patients who do not consent to participate in the
RCT component of the ALICAT study will be inter-
viewed as soon as possible after they have been
approached to participate in the trial. ALICAT RCT
participants and their relatives/carers will be inter-
viewed after they have completed the treatment
phase of the trial, approximately 3 to 12 weeks after
the 26 week treatment date. Participants withdrawing
from the intervention or control arm of the RCT
component of the study will be offered the oppor-
tunity to be interviewed at the point of withdrawal.
As with the focus groups, the qualitative interviews
will follow a topic guide but also allow participants
the flexibility to discuss issues important to them
[36]. Patients who take part in the intervention or
control arms of the trial will be interviewed to
explore: their reasons for, and experiences of, partici-
pating in the trial; their views and attitudes towards
equipoise; and in the case of the intervention partici-
pants, the acceptability of LMWH. Patients who de-
cline randomization will be interviewed to explore
their understanding of trial processes, their experi-
ences of the first five months of LMWH off-trial
and reasons for non-consent. Participants withdraw-
ing from the study will be interviewed to explore the
reasons for their withdrawal and to identify potential
strategies and support necessary to minimize attri-
tion. Recruitment to trials in patients with advanced
cancer is known to be difficult [37] and patient-
reported data in the qualitative arm of this study will
inform strategies for recruitment in a full phase
three RCT. Relatives/carers of patients who take part
in the intervention or control arms of the trial will
be interviewed to explore their experiences of caring
for someone taking part in the ALICAT trial.Data management
The focus groups and patient interviews will be
audio recorded and field-notes will be written to rec-
ord any instances of non-verbal communication or
reaction to any of the discussions. Digital recordings
will be transcribed in full and verbatim. Transcripts
will be anonymized and subsequently uploaded to
QSR NVivo 10 (QSR International) qualitative
software for data management and coding.
Framework analysis
Data will be analyzed to identify problems with sys-
tems and procedures that need addressing as well as
patient attitudes and experiences. The most appro-
priate analytic method to achieve this for both the
focus group and interview data is framework ana-
lysis, an adaptable approach originally developed for
use in applied policy research with clear objectives
[38]. It is a methodical approach that follows a clear
and documented process, but as with other qualita-
tive approaches it relies on the researcher to deter-
mine the quality of the analysis [38]. Framework
analysis will be carried out in line with Ritchie and
Spencer’s five interconnected steps described in
Table 4 [38].
The qualitative components of the study (focus
groups with clinicians and qualitative interviews with
patients and relatives and/or carers) will provide rich
data in relation to the attitudes of clinicians recruit-
ing to the study and to patients and their relatives’
motivations to participate in the trial, perceived ben-
efits and burdens, and reasons for withdrawal from
the trial. The findings of the qualitative study will be
used by the Trial Management Group to assess po-
tential alterations to trial design, and will be used to
complement the reporting of the full trial, where
appropriate.
UK wide survey exercise
This component of the study will comprise telephone
and web-based surveys to develop a classification and
enumeration system for current CAT models and path-
ways of care. The pilot will be used to identify the rele-
vant variables in the CAT journey and shall be used to
develop the most important questions to be asked in the
web-based survey. The survey shall then be distributed as
widely as possible in order to gain a maximum breadth
of understanding pertaining to the patient journey and dif-
ferent service models. Responsibility for the management
of patients with ongoing malignancy post-VTE varies
across different regions; in some, anticoagulation is man-
aged entirely through the hematology service, whilst some
oncology centers will take responsibility for CAT manage-
ment. Other models are known to exist in which a shared
Table 4 Framework analysis - Ritchie and Spencer’s five interconnected steps [38]
Familiarization: The researcher will immerse themselves in the data by re-listening to interview recordings and re-reading transcripts
and field notes. The researcher will document central ideas and recurring themes.
Identifying a thematic
framework:
An index of themes will be created, informed by the original research aims around understanding recruitment and
retention, but also by issues raised by the participants in the data.
Indexing the data: The index will be applied to each transcript by coding them with the themes from the thematic framework. During
this process, the framework may be adjusted, adding new themes and subthemes as they emerge. The adjusted
framework will then be applied to subsequent transcripts and reapplied to existing transcripts to ensure all data is
appropriately coded.
Charting: A matrix will be created of themes and participants. Data will be lifted from the transcripts and arranged according to
thematic references. The data is summarized by the researcher, rather than verbatim quotes included, and referenced
back to the original data.
Mapping and
interpretation:
Charts and research notes will be reviewed to compare and contrast the perceptions and experiences of participants.
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antly in the primary care setting. The survey will be struc-
tured around the patient pathway from identification of a
VTE, early management and late management developed
from the focus groups. We will then undertake a UK wide
survey exercise with relevant stakeholders from primary
and secondary care. This will initially be in the form of a
telephone survey to essentially pilot and clarify the survey
tool. The survey will explore the views and experiences of
relevant clinical stakeholders involved in the CAT journey
from diagnosis to ongoing management, and will include
clinicians and allied health professionals from radiology,
hematology, oncology primary care and pharmacy. Initial
questions shall be designed around the findings from the
focus group data in order to conduct semi-structured in-
terviews. These findings shall then inform the design of a
more extensive web survey sent out to doctors, nurses and
allied health professionals potentially involved in the care
of patients with CAT, and will allow for classification and
enumeration of the models of care. This will also be tri-
angulated with available documentary evidence on path-
ways of care. A particular focus will be on the
management of transition points between settings and
how continuities in care are assured. Respondents will
be encouraged to submit any local documents they use
on care pathways.
Outcome measures
The primary outcome measures are: the number of eli-
gible patients identified over 12 months, the number of
recruited patients (randomized participants) over 12
months (target recruitment rate of 30% of eligible pa-
tients), and the proportion of participants with recurrent
VTEs during trial follow up. VTE will be objectively
confirmed through radiological investigation. DVT will
be confirmed through Doppler ultrasonography or ven-
ography. PE shall be confirmed through a computerized
tomography (CT) pulmonary angiogram. The secondary
outcome measures are: completion of trial protocol, qual-
ity of life, symptom assessment, patients’ and relatives’experiences of taking part in the trial, and the attitudes of
clinicians towards the ALICAT trial.
Completion of trial protocol will be assessed six months
after randomization to ascertain the attrition rate due to
patient choice or death during the study period. Partici-
pants choosing to withdraw from either arm of the study
protocol will be invited to participate in a qualitative inter-
view to explore their reasons for withdrawal.
Quality of life will be measured using the EORTC QLQ-
C30 Version 3.0 and EQ-5D-5 L at three monthly inter-
vals for six months. The EORTC QLQ-C30 [39], Version
3.0, has become a benchmark measure of quality of life
in patients with cancer. It contains five functional scales
(physical, role, cognitive, emotional and social), three
symptom scales (pain, nausea and/or vomiting, and fa-
tigue), global health and quality of life scales, and sev-
eral other single items. The EQ-5D-5 L [40] is a short
quality of life tool, designed to complement other mea-
sures and is recommended by the National Institute for
Health and Care Excellence for use in economic ana-
lyses [41]. The ALICAT study will identify key cost
drivers to inform the design of a future definitive phase
three trial, which will include a cost utility study. Orders
of magnitude of differences in costs and outcomes iden-
tified in the EQ-5D-5 L will help in the estimation of an-
ticipated effect sizes for the full trial.
Symptom assessment will be measured using the
Edmonton Symptom Assessment System Revised (ESAS-r)
at three monthly intervals for six months. The ESAS-r is
used to capture patients’ perspective on their symptoms,
providing an indication of severity of nine symptoms: pain,
tiredness, drowsiness, nausea, lack of appetite, depression,
anxiety, shortness of breath, and wellbeing [42,43]. In
addition, we will look for symptoms which are likely to be
specifically due to VTE (new or worse leg swelling and/or
pain, new or worse breathlessness, pleuritic chest pain).
Ethical, regulatory and management considerations
ALICAT has received ethical and governance approvals
from the South East Wales Research Ethics Committee
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approved to be conducted in the UK by the MHRA. The
study sponsor is Cardiff University. The study protocol
was written with reference to the Research Government
Frameworks for England [44] and Wales [45] and follows
the principles of Good Clinical Practice. Researchers col-
lecting data will have the appropriate research passports,
permissions and letters of access, where required. Written
informed consent will be taken from each participant. All
data will be managed and stored in concordance of Data
Protection Act 1998 [46].
Discussion
The management of CAT is well established, yet uncer-
tainty remains with respect to the length of anticoagula-
tion in some populations. There is currently no trial data
to inform whether continued anticoagulation is warranted
in patients with locally advanced or metastatic cancer after
receiving anticoagulation for six months. Despite the lack
of trial evidence, many clinicians will continue LMWH
and, as such, practice has developed without the evidence
to support it. Whilst there is ultimately a need to deter-
mine whether such patients should receive indefinite
anticoagulation or not, the ALICAT study will first estab-
lish whether recruitment to such a trial would be feasible.
In order to do this, a complex mixed-methods study con-
sisting of a RCT, embedded qualitative study and UK pa-
tient pathways mapping exercise, has been developed with
the intention to proceed to a full RCT if the data shows
that this is feasible.
Trial status
The trial opened to recruitment in December 2013.
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